

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Siliq (brodalumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following que	for this patient that may support a	oproval. Please answer the
Q1. What diagnosis is this drug being prescribed for (pick of	one)?	
☐ Plaque Psoriasis ☐ Other		
Q2. Please provide ICD code for diagnosis.		
Q3. Is the prescriber a Dermatologist?		
☐ Yes ☐ No		
Q4. Does the patient have moderate to severe plaque psoi (BSA)?	riasis affecting greater than 10% o	f body surface area
☐ Yes ☐ No		
Q5. Does the patient have moderate to severe plaque psor or genitals?	riasis affecting crucial body areas	such as hands, feet, face,
☐ Yes ☐ No		
Q6. Has the patient failed at least TWO TOPICAL treatment analogues, Vitamin D analogue/corticosteroid combination		icosteroids, Vitamin D
☐ Yes ☐ No		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Siliq (brodalumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:
Patient Name:	Supervising Physician:
Q7. Has the patient failed or does the patient have a contra	aindication to phototherapy (UVB or PUVA)?
☐ Yes ☐ No	
Q8. Has the patient failed or does the patient have a contra leflunomide, sulfasalazine, OR tacrolimus?	aindication to methotrexate, cyclosporine, acitretin,
☐ Yes ☐ No	
Q9. Please select all of the following agents that the patient Humira Enbrel Cosentyx Remicade Stelara Other	t has failed, has an intolerance or contraindication to:
Pharmacy claim (drug to be billed as a PHARMACY be to this specific member)	enefit claim and dispensed by pharmacy directly to member) enefit claim, but shipped direct to provider to be administered MEDICAL benefit claim as an expense to the provider, and
Q11. If billing as a MEDICAL claim, what provider will be lift reimbursement)? Provide Name and NPI Individual prescriber Provider or specialty group Facility	nked to the claim (i.e. who is the billing entity seeking
Q12. Additional comments	



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Siliq (brodalumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:
Prescriber Signature	Date
r resember signature	Date

seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document